Purchaser
—
Country
United States
Notice published
6 Mar 2026
Tenqual indexed
8 Mar 2026
Closing date
11 Mar 2026
Source ID
Docs found
—
Save this notice and create a tender alert for similar public opportunities.
3 files identified
Create a free account to open the 3 files linked to this notice.
- Create one free tender alert.
- See a short explanation of why each tender matches.
- Upgrade later when you want help planning and writing the bid.
Tender summary
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Office of Logistics and Acquisitions intends to negotiate on an other than full and open competition basis with the following vendor: BD Biosciences. Acquistion Description: To purchase all reagents and consumables on an as-needed basis for clinical patient-care quality control flow cytometry assays by using FACSLyris flow cytometer instrument from BD Bioscience. Each time the instrument is used, fresh vials of monoclonal antibodies, assay quality controls, buffers, fluids, and disposable components must be used. This contract is to purchase the monoclonal antibodies, assay quality controls, buffer, sheath fluids, and disposable components. The monoclonal antibodies are sold as sterile single use vials. For each procedure one to four vials are used. The Center of Cellular Engineering, Department of Transfusion Medicine is an AABB-accredited cellular therapy laboratory whose central mission is to provide services to support NIH's intramural clinical trials. CCE produces clinical therapies from cells collected from NIH Clinical Center (CC) patients and healthy donors. The products are manufactured by the laboratory are used to treat patients with cancer, hematological malignancies, marrow failure, congenital immune disorders, and autoimmune diseases. Products are manufactured using US Food and Drug Administration (FDA) guidelines for manufacturing practices. BD Biosciences is a leading provider of flow cytometry instruments, reagents, and assay solutions used in clinical quality control (QC) and patient-care testing. BD Biosciences offers a comprehensive portfolio of validated antibodies, controls, and reagents that support immunophenotyping, in-process testing, and lot release flow cytometry assays performed under regulated clinical laboratory environments. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-CC-26-002633) by 11:00 AM eastern standard time on 03/11/2026 to: valerie.gregorio@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. Solicitation Number: NOI-CC-26-002633 Type: Special Notice Base Type: Special Notice NAICS: 334516 Classification Code: 6550 Response Deadline: 2026-03-11T12:00:00-04:00 Office Address: Bethesda, MD Place of Performance: Bethesda, Maryland, 20892
What to check before bidding
- Located in United States.
- Source notice 4a8d25c9564d4f39a534d35f3c9c9f0d on SAM.gov.
- Notice published 6 Mar 2026; Tenqual indexed it 8 Mar 2026.
- Deadline listed as 11 Mar 2026.
- 3 tender documents identified.
- Create a free tender alert to catch similar opportunities before the deadline pressure starts.